COMMUNIQUÉS West-GlobeNewswire
-
Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
09/03/2026 -
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
09/03/2026 -
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026
09/03/2026 -
CenTrak Showcases Next Generation of AI-Enhanced Location Intelligence Platform at HIMSS 2026
09/03/2026 -
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
09/03/2026 -
Hyperion DeFi Announces Private Lending Pool Built by HyperLend
09/03/2026 -
Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
09/03/2026 -
BeautyHealth Expands Skin Health Ecosystem with Growing Adoption of SkinStylus Nano-Channeling, a Popular Pairing with Hydrafacial Treatments
09/03/2026 -
SS Innovations Announces Completion of an $18.6 Million Private Placement to Support Growth Initiatives
09/03/2026 -
InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results
09/03/2026 -
Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026
09/03/2026 -
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
09/03/2026 -
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12
09/03/2026 -
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼
09/03/2026 -
NovelMed Therapeutics Announces Regulatory Clearance for Subcutaneous Ruxoprubart and Reports Positive Phase II Intravenous Monotherapy Results in PNH
09/03/2026 -
Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
09/03/2026 -
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026
09/03/2026 -
SRx Health Solutions Launches EventHorizonIQ Subscription for Individual and Institutional Traders
09/03/2026 -
Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models
09/03/2026
Pages